Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.
About
EnteroBiotix is a clinical-stage microbiome therapeutics company focused on transforming the standard of care for patients with gastrointestinal disease. Their lead investigational product, EBX-102-02, is an orally delivered, full-spectrum microbiome drug in clinical development for irritable bowel syndrome (IBS) and other gastrointestinal and liver-related diseases. EBX-102-02 is a high-diversity microbial product manufactured using proprietary AMPLA™ drying technology.
Tags
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does EnteroBiotix do?
EnteroBiotix is a clinical-stage microbiome therapeutics company focused on transforming the standard of care for patients with gastrointestinal disease. Their lead investigational product, EBX-102-02, is an orally delivered, full-spectrum microbiome drug in clinical development for irritable bowel syndrome (IBS) and other gastrointestinal and liver-related diseases. EBX-102-02 is a high-diversity microbial product manufactured using proprietary AMPLA™ drying technology.
How much funding has EnteroBiotix raised?
EnteroBiotix has raised a total of $41M in funding. The most recent round on record is Funding Round.
Where is EnteroBiotix headquartered?
EnteroBiotix is headquartered in Glasgow, United Kingdom.
When was EnteroBiotix founded?
EnteroBiotix was founded in 2017.
What industry does EnteroBiotix operate in?
EnteroBiotix operates in Biotechnology, Pharmaceuticals, Healthcare, Life Sciences, Microbiome, Biotech.